A2M management have completely missed the boat on this one. BUB BOD proactive and got the result, A2M reactive and slow to react. disappointed to say the least considering they already have their tentacles in the US market, hoping for good results across Q4 and FY reporting
Ann: Deferral of FDA consideration of enforcement discretion, page-2
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.79 |
Change
0.160(2.41%) |
Mkt cap ! $4.908B | |||
| Open | High | Low | Value | Volume |
| $6.60 | $6.82 | $6.59 | $20.55M | 3.041M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14149 | $6.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.80 | 15600 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.81 |
Change
0.160 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $6.60 | $6.82 | $6.60 | 946404 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| A2M (ASX) Chart |